CEO SUMMARY: Given the specific news stories that make up THE DARK REPORT’S list of the “Top Ten Lab Stories for 2011,” it might be said that 2011 was a rather quiet year overshadowed by anticipation of the coming reforms mandated by the Accountable Care Act of 2010. For the clinical lab testing industry, 2011 […]
2011’s Top 10 Lab Stories Point to a Busy 2012
Few “earthquake news events” during a year when many were anticipating ObamaCare reforms
- By Robert Michel
- > From the Volume XIX No. 1 - January 9, 2012 Issue
- Tags: accountable care, accountable care act, Accountable care organizations, aco, Anatomic pathology, anti kickback statute, cap, clinical lab, clinical lab test, clinical lab testing, clinical lab tests, clinical laboratories, Clinical Laboratory, clinical laboratory industry, clinical laboratory test, clinical laboratory testing, clinical laboratory testing market, clinical laboratory tests, clinical labs, cpt, cpt code, dark report, diagnostic assays, electronic medical record, electronic medical records, emr, emr system, emr systems, Fee-for-service, genetic test, genetic tests, hie, impac, informatics, lab acquisition, lab administrator, lab industry, lab manager, lab managers, lab test, lab test companies, lab test prices, lab testing, lab testing companies, lab tests, laboratories, laboratory acquisitions, laboratory companies, laboratory industry, laboratory information, laboratory information system, laboratory information systems, laboratory organization, laboratory organizations, laboratory test, laboratory test costs, laboratory testing, laboratory testing services, laboratory tests, local coverage determination, local coverage determinations, managed care, managed care companies, Meaningful Use, meaningful use guidelines, medical home, medical homes, medical records, Medicare, Medicare Part B, MolDx, molecular assay, molecular assays, molecular diagnostic, molecular diagnostic assays, molecular tests, pathologists, Pathology group, pathology groups, pathology test, pathology testing, patient record, private payer, stage 2 meaningful use, the clinical laboratory, the dark report, the laboratory, Value-based reimbursement
